Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N‑[(2′,4′‑Difluoro‑4‑hydroxy‑5‑iodobiphenyl‑3‑yl)carbonyl]‑beta-alanine is an experimental small molecule compound belonging to the biphenyl derivatives class. It has a molecular formula of C16H12F2INO4 and a molecular weight of approximately 447.17 g/mol[1][6][7]. The compound is not approved for any clinical use and there are no known indications or associated conditions in regulatory databases or clinical trial registries[6]. Its mechanism of action, biological targets, pharmacological activity, and therapeutic potential have not been described in publicly available sources as of June 2025.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-[(2',4'-difluoro-4-hydroxy-5-iodobiphenyl-3-yl)carbonyl]-beta-alanine.